Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease

BACKGROUND: Bapineuzumab, a humanized anti–amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer’s disease. METHODS: We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer’s disease — one...

Full description

Saved in:
Bibliographic Details
Main Authors: Salloway, Stephen, Sperling, Reisa, Fox, Nick C., Blennow, Kaj, Klunk, William, Raskind, Murray, Sabbagh, Marwan, Honig, Lawrence S., Porsteinsson, Anton P., Ferris, Steven, Reichert, Marcel, Ketter, Nzeera, Nejadnik, Bijan, Guenzler, Volkmar, Miloslavsky, Maja, Wang, Daniel, Lu, Yuan, Lull, Julia, Tudor, Iulia Cristina, Liu, Enchi, Grundman, Michael, Yuen, Eric, Black, Ronald, Brashear, H. Robert
Format: Artigo
Language:Inglês
Published: 2014
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4159618/
https://ncbi.nlm.nih.gov/pubmed/24450891
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1304839
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items